CA2732686C - Compositions de modulateur de cellules sensorielles auriculaires a liberation controlee et procedes de traitement de troubles otiques - Google Patents
Compositions de modulateur de cellules sensorielles auriculaires a liberation controlee et procedes de traitement de troubles otiques Download PDFInfo
- Publication number
- CA2732686C CA2732686C CA2732686A CA2732686A CA2732686C CA 2732686 C CA2732686 C CA 2732686C CA 2732686 A CA2732686 A CA 2732686A CA 2732686 A CA2732686 A CA 2732686A CA 2732686 C CA2732686 C CA 2732686C
- Authority
- CA
- Canada
- Prior art keywords
- auris
- agent
- formulation
- otic
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14003308P | 2008-12-22 | 2008-12-22 | |
US61/140,033 | 2008-12-22 | ||
US16023309P | 2009-03-13 | 2009-03-13 | |
US61/160,233 | 2009-03-13 | ||
US16481209P | 2009-03-30 | 2009-03-30 | |
US61/164,812 | 2009-03-30 | ||
GB0907070A GB2461962B (en) | 2008-07-25 | 2009-04-24 | Slow release NMDA receptor antagonist for otic disorders |
GB0907070.7 | 2009-04-24 | ||
US17442109P | 2009-04-30 | 2009-04-30 | |
US61/174,421 | 2009-04-30 | ||
US12/504,553 US8496957B2 (en) | 2008-07-21 | 2009-07-16 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
US12/504,553 | 2009-07-16 | ||
PCT/US2009/067552 WO2010074992A2 (fr) | 2008-12-22 | 2009-12-10 | Compositions de modulateur de cellules sensorielles auriculaires à libération contrôlée et procédés de traitement de troubles otiques |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2732686A1 CA2732686A1 (fr) | 2010-07-01 |
CA2732686C true CA2732686C (fr) | 2017-10-03 |
Family
ID=42288363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2732686A Expired - Fee Related CA2732686C (fr) | 2008-12-22 | 2009-12-10 | Compositions de modulateur de cellules sensorielles auriculaires a liberation controlee et procedes de traitement de troubles otiques |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2299976A4 (fr) |
JP (4) | JP6013736B2 (fr) |
CN (2) | CN106344495A (fr) |
AU (1) | AU2009330458B2 (fr) |
CA (1) | CA2732686C (fr) |
WO (1) | WO2010074992A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6170047B2 (ja) | 2011-08-31 | 2017-07-26 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | アポトーシス−ターゲティングナノ粒子 |
ES2669561T3 (es) | 2012-02-17 | 2018-05-28 | University Of Georgia Research Foundation, Inc. | Nanopartículas para el transporte mitocondrial de agentes |
US10398663B2 (en) | 2014-03-14 | 2019-09-03 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
US20170216439A1 (en) * | 2014-07-29 | 2017-08-03 | Otonomy, Inc. | Otic formulations for the treatment of ceruminosis |
MX2018001571A (es) | 2015-08-05 | 2018-09-06 | Childrens Medical Center | Composiciones con potenciadores de permeacion para suministro de farmacos. |
CA3026007A1 (fr) | 2016-05-18 | 2017-11-23 | Sound Pharmaceuticals Incorporated | Traitement de la maladie de meniere |
JP7277360B2 (ja) * | 2016-09-14 | 2023-05-18 | ザ チルドレンズ メディカル センター コーポレーション | 薬物送達のための透過促進剤を有する組成物 |
CN109922812A (zh) * | 2016-09-16 | 2019-06-21 | 维京治疗公司 | 减少与甲状腺相关的副作用的方法 |
US11202789B2 (en) | 2016-11-21 | 2021-12-21 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
WO2018112815A1 (fr) * | 2016-12-22 | 2018-06-28 | Nanjing University | Modèle animal pour syndrome de perte auditive et sa méthode t de traitement |
US11707472B2 (en) | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
MX2020009843A (es) | 2018-03-22 | 2020-12-11 | Viking Therapeutics Inc | Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto. |
WO2020045162A1 (fr) * | 2018-08-30 | 2020-03-05 | 学校法人慶應義塾 | Support d'administration de médicament |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
EP0551626A1 (fr) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Gel thermoréversible utile comme excipient pharmaceutique pour une formation galénique |
EP1109563A4 (fr) * | 1998-08-04 | 2009-07-22 | Madash Llp | Hydrogels sensibles a la chaleur a terminaison modifiee |
US6998137B2 (en) * | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
US6589549B2 (en) * | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US7589110B2 (en) * | 2002-09-06 | 2009-09-15 | Durect Corporation | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
WO2004022069A1 (fr) * | 2002-09-06 | 2004-03-18 | Durect Corporation | Administration dans l'oreille interne de modulateurs de la neurotransmission glutamatergique |
US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
JP2005220070A (ja) * | 2004-02-05 | 2005-08-18 | Medgel Corp | 神経再生および保護のための生体吸収性高分子ハイドロゲル製剤 |
US20060063802A1 (en) * | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US8268866B2 (en) * | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
JP2006111585A (ja) * | 2004-10-15 | 2006-04-27 | Mebiol Kk | 徐放性組成物およびその徐放方法 |
US20060205789A1 (en) * | 2005-03-04 | 2006-09-14 | Neurosystec Corporation | Gacyclidine formulations |
EA017264B1 (ru) * | 2005-09-28 | 2012-11-30 | Аурис Медикаль Аг | Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха |
TW201336514A (zh) * | 2006-04-13 | 2013-09-16 | Alcon Res Ltd | RNA干擾(RNAi)所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用(二) |
KR20210107137A (ko) * | 2008-04-21 | 2021-08-31 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
WO2009139924A2 (fr) * | 2008-05-14 | 2009-11-19 | Otonomy, Inc. | Compositions de corticostéroïdes à libération contrôlée et procédés pour le traitement de troubles otiques |
-
2009
- 2009-12-10 EP EP09835529.0A patent/EP2299976A4/fr not_active Withdrawn
- 2009-12-10 CA CA2732686A patent/CA2732686C/fr not_active Expired - Fee Related
- 2009-12-10 CN CN201610730867.1A patent/CN106344495A/zh active Pending
- 2009-12-10 CN CN2009801305625A patent/CN102112111A/zh active Pending
- 2009-12-10 AU AU2009330458A patent/AU2009330458B2/en not_active Ceased
- 2009-12-10 JP JP2011542272A patent/JP6013736B2/ja not_active Expired - Fee Related
- 2009-12-10 WO PCT/US2009/067552 patent/WO2010074992A2/fr active Application Filing
-
2015
- 2015-05-07 JP JP2015095099A patent/JP6207093B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-26 JP JP2017087624A patent/JP2017160232A/ja active Pending
-
2018
- 2018-04-24 JP JP2018083451A patent/JP2018138585A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2299976A2 (fr) | 2011-03-30 |
WO2010074992A3 (fr) | 2010-10-21 |
JP2018138585A (ja) | 2018-09-06 |
EP2299976A4 (fr) | 2014-07-23 |
AU2009330458A1 (en) | 2010-07-01 |
AU2009330458B2 (en) | 2013-08-22 |
JP6013736B2 (ja) | 2016-10-25 |
CN102112111A (zh) | 2011-06-29 |
JP2012513394A (ja) | 2012-06-14 |
CN106344495A (zh) | 2017-01-25 |
WO2010074992A2 (fr) | 2010-07-01 |
JP2015164943A (ja) | 2015-09-17 |
JP2017160232A (ja) | 2017-09-14 |
CA2732686A1 (fr) | 2010-07-01 |
JP6207093B2 (ja) | 2017-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9808460B2 (en) | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | |
US10918594B2 (en) | Controlled-release CNS modulating compositions and methods for the treatment of otic disorders | |
CA2732686C (fr) | Compositions de modulateur de cellules sensorielles auriculaires a liberation controlee et procedes de traitement de troubles otiques | |
US8399018B2 (en) | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | |
US9867778B2 (en) | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | |
US20190192425A1 (en) | Controlled release delivery devices for the treatment of otic disorders | |
US9427472B2 (en) | Controlled release compositions for modulating free-radical induced damage and methods of use thereof | |
US10232044B2 (en) | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders | |
US8349353B2 (en) | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders | |
JP2016164164A (ja) | 耳の不調の治療用の制御放出性の抗菌性組成物および方法 | |
AU2020230269B2 (en) | Auris formulations for treating otic diseases and conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20191210 |